Humana (NYSE:HUM) Releases FY24 Earnings Guidance

Humana (NYSE:HUM) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of approx. $16.00 for the period, compared to the consensus estimate of $16.35.

Humana Stock Down 1.8 %

Humana stock opened at $305.91 on Friday. The company has a 50-day simple moving average of $327.77 and a 200-day simple moving average of $394.49. The firm has a market capitalization of $36.86 billion, a P/E ratio of 19.05, a P/E/G ratio of 1.82 and a beta of 0.45. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.59 and a current ratio of 1.67. Humana has a one year low of $299.23 and a one year high of $541.21.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. The business had revenue of $29.61 billion during the quarter, compared to analyst estimates of $28.52 billion. Humana had a net margin of 1.82% and a return on equity of 17.76%. The company’s quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $9.38 earnings per share. As a group, equities analysts expect that Humana will post 16.07 earnings per share for the current year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is currently 22.04%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HUM. Truist Financial reaffirmed a hold rating and issued a $550.00 price objective on shares of Humana in a report on Friday, January 19th. TheStreet lowered shares of Humana from a b rating to a c+ rating in a research report on Monday, January 8th. Cantor Fitzgerald reduced their price objective on shares of Humana from $391.00 to $360.00 and set a neutral rating for the company in a research report on Thursday. Barclays reduced their price objective on shares of Humana from $356.00 to $310.00 and set an equal weight rating for the company in a research report on Tuesday, April 2nd. Finally, StockNews.com lowered shares of Humana from a strong-buy rating to a hold rating in a research report on Friday, January 26th. Eleven investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, Humana currently has an average rating of Hold and an average price target of $433.74.

Insider Transactions at Humana

In related news, Director Jorge S. Mesquita purchased 545 shares of Humana stock in a transaction dated Tuesday, February 20th. The stock was acquired at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares of the company’s stock, valued at $946,358.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is owned by insiders.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.